A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids

STUDY QUESTION: What is the safety and efficacy profile during long-term (12–24 months) uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 and 25 mg in women with heavy menstrual bleeding (HMB) associated with uterine fibroids? SUMMARY ANSWER: Uninterrupted tre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hum Reprod Open
Autors principals: Diamond, M P, Stewart, E A, Williams, A R W, Carr, B R, Myers, E R, Feldman, R A, Elger, W, Mattia-Goldberg, C, Schwefel, B M, Chwalisz, K
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6870550/
https://ncbi.nlm.nih.gov/pubmed/31777761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/hropen/hoz027
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars